Vyleesi
Product Images NDC 80064-141

Product Visual Gallery

This gallery contains 19 technical images submitted to the FDA as part of the official labeling for Vyleesi (NDC 80064-141). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Palatin Technologies, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Vyl00 0002 01

A forest plot chart showing the ratio and 95% confidence intervals for pharmacokinetic parameters (AUC and Cmax) of various coadministered drugs including amlodipine, bupropion, celecoxib, and others. The x-axis ranges from 0 to 2, with a vertical line at 1 indicating no effect. Each drug is listed on the y-axis with corresponding points and error bars representing the ratio and confidence intervals for AUC and Cmax values.*

FDA Label Image

Vyl00 0002 02

A set of two bar charts labeled Study 1 and Study 2 comparing the percent of patients with increases in FSFI-Desire Domain scores from baseline to the end of the treatment period. Each chart shows data for patients treated with Vyleesi versus placebo across multiple score increase ranges. The vertical axis represents percent of patients, and the horizontal axis shows increases in FSFI-Desire Domain score.*

FDA Label Image

Vyl00 0002 03

Two bar charts labeled Study 1 and Study 2 showing the percentage of patients versus the decrease in FSDS-DAO Q13 Score from baseline to end of treatment period. Each chart compares treatment with Vyleesi and placebo across four categories of score decrease.*

FDA Label Image

Vyl00 0002 04

Instructional text panel for Vyleesi (bremelanotide) injection, showing dosage of 1.75 mg/0.3 mL for subcutaneous use only. The panel is titled "Instructions for Use" with the product name and proper usage details on a black background with pink border and text.*

FDA Label Image

Vyl00 0002 05

Instructional illustration of the Vyleesi auto-injector showing its parts before and after use. The diagram labels the expiration date, view window with gray tip indicating readiness, clear cap before use, and purple window with tip indicating injection completion after use.*

FDA Label Image

Vyl00 0002 06

FDA Label Image

Vyl00 0002 07

Illustration labeled Step 1 titled 'Check Supplies,' showing a Vyleesi medication pen injector with a purple cap inside a pink circle, indicating the first step in the medication usage process.*

FDA Label Image

Vyl00 0002 08

An instructional diagram showing a front view of a human torso and upper legs highlighted in pink to indicate areas for injection. The image includes a note stating to inject only into the stomach area (abdomen) or thigh. It is labeled as Step 2, titled 'Get Ready.'*

FDA Label Image

Vyl00 0002 09

Illustration showing Step 3 in preparing and giving an injection for Vyleesi. The first circle depicts a person's hand removing a protective cap from the injection device, indicated by an arrow. The second circle demonstrates administering the injection into the abdomen area.*

FDA Label Image

Vyl00 0002 10

Instructional illustrations showing use of the Vyleesi injection pen. The first image advises to listen for a second click about 2 seconds after injection. The second image advises to wait 5 seconds after the injection click before removing the pen.*

FDA Label Image

Vyl00 0002 11

This image shows a text panel labeled 'Step 4.' The visible text instructs to 'Check That the Medicine was Given.' It appears to be part of a medication administration or safety checklist, emphasizing verifying that the medicine was administered.*

FDA Label Image

Vyl00 0002 12

Illustration showing a close-up detail of Vyleesi, focusing on a specific area marked with an arrow and a circular magnified inset. The image is likely part of instructional content related to the product's use or identification.*

FDA Label Image

Vyl00 0002 13

A text excerpt labeled Step 5, instructing to check the injection site. The text is a fragment, likely part of a multi-step instruction related to injection procedure.*

FDA Label Image

Vyl00 0002 14

FDA Label Image

Vyl00 0002 15

An instructional illustration for Vyleesi autoinjector disposal. It advises to throw away the VYLEESI autoinjector, accompanied by a graphic of a sharps disposal container and a caution to keep the container out of children’s reach.*

FDA Label Image

Vyl00 0002 16

Packaging label for Vyleesi by Palatin Technologies, Inc. Displays company logo and contact information including address in Cranbury, NJ, phone number, email, and website. The label also contains an area marked 'FPO' indicating a placeholder for a barcode and the issue date February 2021.*

FDA Label Image

Vyl00 0002 17

Vyleesi (bremelanotide injection) 1.75 mg/0.3 mL sterile solution packaging label. The carton is primarily black with pink accents, showing active ingredient bremelanotide equivalent to 1.89 mg bremelanotide acetate, and inactive ingredients including glycerin and pH adjusters. The product is for subcutaneous use only, manufactured by Palatin Technologies, with NDC 80064-141-02 visible on the label.*

FDA Label Image

Vyl00 0002 18

Packaging label for Vyleesi (bremelanotide injection) by Palatin Technologies. The label states the strength as 1.75 mg/0.3 mL for subcutaneous use only. It includes active ingredient information, inactive ingredients, manufacturer details, and storage instructions. The label also notes the pack contains 4 single-dose autoinjectors.*

FDA Label Image

Vyl00 0002 19

Vyleesi (bremelanotide injection) 1.75 mg/0.3 mL single-dose autoinjector label for subcutaneous use only. The label includes storage instructions and dosing limits, indicates Rx only, and shows it is manufactured for Palatin Technologies, Inc. The NDC is 80064-141-01.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.